Dysregulation of the JAK-STAT pathway is a key driver in the pathogenesis of leukemia, and understanding the intricate molecular mechanisms behind JAK2 mutations and their downstream effects is crucial for the development of effective therapies. Here, JAK2 is linked to leukemia.